Outlook Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Outlook Therapeutics

12/08/2026 13:44

Outlook Therapeutics Inc OTLK.OQ OTLK.O is expected to  show a rise in quarterly revenue when it reports  results on August 14 for the period ending June 30 2026
The Iselin New Jersey-based  company is expected to report a 252.2% increase in revenue to $5.3 million from $1.51 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Outlook Therapeutics Inc is for a loss of 9 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Outlook Therapeutics Inc is $5.00, about 342.5% above its last closing price of $1.13
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.14
-0.12
-0.16
Missed
-33.3
Dec. 31 2026
-0.27
-0.17
-0.22
Missed
-26.9
Sep. 30 2025
-0.21
-0.25
-0.19
Beat
25​
Jun. 30 2025
-0.30
-0.39
-0.55
Missed
-39.8
​​Mar. 31 2025
-0.52
-0.60
-0.40
Beat
33.1
Dec. 31 2024
-0.69
-0.77
0.72
Beat
192.9​
Sep. 30 2024
-0.86
-0.83
0.76
Beat
191.1
Jun. 30 2024
-1.02
-1.00
-0.83
Beat
16.8
This summary was machine generated August 12 at 12:44 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)